×
About 5,659 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  2,667 results

The expression of substance P and calcitonin gene-related peptide is associated with th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898744
BMC Musculoskeletal Disorders; Han SH, Kim HK et. al.

Feb 22nd, 2021 - In this study, we investigated whether substance P (SP) or calcitonin gene-related peptide (CGRP) expression is associated with tendon degeneration in patients with lateral epicondylitis. Twenty-nine patients who underwent surgical treatment for l...

Understanding the migraine treatment landscape prior to the introduction of calcitonin ...
https://doi.org/10.1111/head.14053
Headache Kawata AK, Shah N et. al.

Feb 17th, 2021 - Calcitonin gene-related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the pattern...

Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers...
https://doi.org/10.1177/0333102421996345
Cephalalgia : an International Journal of Headache; de Tommaso M, Delussi M et. al.

Feb 17th, 2021 - Erenumab is a monoclonal antibody against calcitonin gene-related peptide receptors, which showed efficacy in migraine attack prevention. The aims of the present pilot study were to i) evaluate the effect of single dose of Erenumab 70 mg on laser ...

Erenumab patient characteristics, medication adherence, and treatment patterns in the U...
https://doi.org/10.1111/head.14068
Headache Hines DM, Shah S et. al.

Feb 17th, 2021 - To describe patient characteristics, adherence, and treatment patterns, among adult migraine patients in the United States prescribed erenumab. Migraine is a highly prevalent and debilitating disease characterized by recurrent attacks of moderate ...

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likeli...
https://doi.org/10.1177/0333102421989601
Cephalalgia : an International Journal of Headache; Drellia K, Kokoti L et. al.

Feb 11th, 2021 - Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-head comparisons with esta...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734227
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 17th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  2,805 results

The expression of substance P and calcitonin gene-related peptide is associated with th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898744
BMC Musculoskeletal Disorders; Han SH, Kim HK et. al.

Feb 22nd, 2021 - In this study, we investigated whether substance P (SP) or calcitonin gene-related peptide (CGRP) expression is associated with tendon degeneration in patients with lateral epicondylitis. Twenty-nine patients who underwent surgical treatment for l...

Understanding the migraine treatment landscape prior to the introduction of calcitonin ...
https://doi.org/10.1111/head.14053
Headache Kawata AK, Shah N et. al.

Feb 17th, 2021 - Calcitonin gene-related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the pattern...

Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers...
https://doi.org/10.1177/0333102421996345
Cephalalgia : an International Journal of Headache; de Tommaso M, Delussi M et. al.

Feb 17th, 2021 - Erenumab is a monoclonal antibody against calcitonin gene-related peptide receptors, which showed efficacy in migraine attack prevention. The aims of the present pilot study were to i) evaluate the effect of single dose of Erenumab 70 mg on laser ...

Erenumab patient characteristics, medication adherence, and treatment patterns in the U...
https://doi.org/10.1111/head.14068
Headache Hines DM, Shah S et. al.

Feb 17th, 2021 - To describe patient characteristics, adherence, and treatment patterns, among adult migraine patients in the United States prescribed erenumab. Migraine is a highly prevalent and debilitating disease characterized by recurrent attacks of moderate ...

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likeli...
https://doi.org/10.1177/0333102421989601
Cephalalgia : an International Journal of Headache; Drellia K, Kokoti L et. al.

Feb 11th, 2021 - Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-head comparisons with esta...

see more →

News  181 results

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.staging.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

FDA Drug Approvals, Internal Medicine — 2020 Midyear Review
https://reference.staging.medscape.com/viewarticle/935373

Aug 13th, 2020 - Gastroenterology Pizensy (lactitol) Lactitol exerts an osmotic effect, causing an influx of water into the small intestine that results in a laxative effect in the colon. It is indicated for adults with chronic idiopathic constipation . Approval w...

Galcanezumab Looks Promising for Treatment-Resistant Migraine
https://www.medscape.com/viewarticle/931296

May 27th, 2020 - The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches. "Th...

Galcanezumab Looks Promising for Treatment-Resistant Migraine
https://www.staging.medscape.com/viewarticle/931296

May 27th, 2020 - The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches. "Th...

see more →